OPTIMER PHARMACEUTICALS INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 21 rows in 2009. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2009-12-02: Reporting owner ZERBE ROBERT L MD; Form 4; Security Stock option - right to buy; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2009-04-06: Reporting owner Gorbach MD Sherwood; Form 4; Security Stock option - right to buy; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2009-02-19: Reporting owner Frapaise Francois-Xavier; Form 4/A; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2009-02-19: Reporting owner Frapaise Francois-Xavier; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2009-12-02 | ZERBE ROBERT L MD Director | 4 | Stock option - right to buy Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $10.90 exercise price | 2009-12-04 | |
| 2009-04-06 | Gorbach MD Sherwood Officer (Senior VP, Chief Medical Offic) | 4 | Stock option - right to buy Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.68 exercise price | 2009-04-08 | |
| 2009-02-19 | Frapaise Francois-Xavier Officer (Chief Scientific Officer) | 4/A | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,000 120,000 owned after | $10.85 exercise price | 2010-01-12 | |
| 2009-02-19 | Frapaise Francois-Xavier Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,000 120,000 owned after | $10.85 exercise price | 2009-02-23 | |
| 2009-02-19 | GREBOW PETER E Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $10.85 exercise price | 2009-02-23 | |
| 2009-02-19 | GREBOW PETER E Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 15,000 owned after | $10.85 exercise price | 2009-02-23 | |
| 2009-01-08 | SCHREIBER ALAIN Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $10.75 exercise price | 2009-01-12 | |
| 2009-01-08 | CHANG JOSEPH Y Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $10.75 exercise price | 2009-01-12 | |
| 2009-01-08 | AUERBACH MARK Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $10.75 exercise price | 2009-01-12 | |
| 2009-01-08 | ALTIG ANTHONY E Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $10.75 exercise price | 2009-01-12 | |
| 2009-01-08 | Poulos Kevin P Officer (Chief Commercial Officer) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Shue Youe Kong Officer (VP Clinical Development) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Prunty John D Officer (CFO) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Che Tessie M Officer (COO and SVP) | 4 | Stock option (right to buy) Derivative · Direct · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Che Tessie M Officer (COO and SVP) | 4 | Stock option (right to buy) Derivative · Indirect · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Chang Michael N Director, Officer (CEO and President) | 4 | Stock option (right to buy) Derivative · Direct · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-08 | Chang Michael N Director, Officer (CEO and President) | 4 | Stock option (right to buy) Derivative · Indirect · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $10.75 exercise price | 2009-01-09 | |
| 2009-01-07 | Che Tessie M Officer (COO and SVP) | 4 | Stock option (right to buy)8 Derivative · Direct · (m) | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +20,769 0 owned after | $0.65 exercise price | 2009-01-09 | |
| 2009-01-07 | Che Tessie M Officer (COO and SVP) | 4 | Stock option (right to buy) Derivative · Indirect · (m) | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +30,769 0 owned after | $0.22 exercise price | 2009-01-09 | |
| 2009-01-07 | Chang Michael N Director, Officer (CEO and President) | 4 | Stock option (right to buy) Derivative · Direct · (m) | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +30,769 0 owned after | $0.22 exercise price | 2009-01-09 | |
| 2009-01-07 | Chang Michael N Director, Officer (CEO and President) | 4 | Stock option (right to buy) Derivative · Indirect · (m) | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +20,769 0 owned after | $0.65 exercise price | 2009-01-09 |